Ballenger J C
Department of Psychiatry and Behavioral Sciences, Medical University of South Carolina, Charleston, USA.
J Clin Psychopharmacol. 1996 Jun;16(3 Suppl 2):29S-35S; discussion 35S-36S. doi: 10.1097/00004714-199606002-00007.
Recent studies have shown venlafaxine to be an effective first-line agent for patients who have depression of varying severity. Two representative clinical trials to assess the efficacy of venlafaxine were reviewed: one in severely ill hospitalized patients and the other in outpatients. Efficacy was assessed using scores on several rating scales for 93 inpatients in the placebo-controlled trial and 224 outpatients in the active-control trial. Demographics and baseline scores were similar among study patients in each trial. In both trials, venlafaxine was significantly more effective than placebo. The study of inpatients demonstrated a rapid onset of antidepressant efficacy of venlafaxine and a reduction in comorbid symptoms of anxiety. In the study of outpatients, anticholinergic side effects commonly associated with tricyclic antidepressants such as imipramine were not found to be associated with venlafaxine, although some nausea occurred. Results of these clinical studies confirm those of previous studies that have shown venlafaxine to be an effective first-line agent for the management of depression in both hospitalized patients and outpatients.
最近的研究表明，文拉法辛对不同严重程度的抑郁症患者是一种有效的一线治疗药物。本文回顾了两项评估文拉法辛疗效的代表性临床试验：一项针对重症住院患者，另一项针对门诊患者。在安慰剂对照试验中，对93名住院患者使用几种评定量表的评分来评估疗效；在活性对照试验中，对224名门诊患者进行评估。每项试验中研究患者的人口统计学特征和基线评分相似。在两项试验中，文拉法辛均比安慰剂显著更有效。住院患者的研究表明，文拉法辛的抗抑郁疗效起效迅速，且共病焦虑症状有所减轻。在门诊患者的研究中，未发现与三环类抗抑郁药（如丙咪嗪）常见的抗胆碱能副作用与文拉法辛有关，尽管出现了一些恶心症状。这些临床研究结果证实了先前研究的结果，即文拉法辛是治疗住院患者和门诊患者抑郁症的有效一线药物。
